



HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials

LOS ANGELES, California and PARIS, May 10, 2021 - HTL, the world leader in biotechnology solutions based on hyaluronic acid (HA) and other biopolymers and the Terasaki Institute for Biomedical Innovation (TIBI), a US-based research institute at the frontier of personalized and precision medicine, announced their Memorandum of Understanding (MOU) to explore the creation of a joint research program. This program will focus on biomaterials for translational programs combining TIBI's microneedle and bioprinting technologies with HTL's expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.

"This MOU demonstrates HTL's strong commitment to innovation, both internally and externally. We look forward to working with the Terasaki Institute and translating today's technologies in tomorrow's medicines" said HTL Deputy CEO Charles Ruban.

"The Terasaki Institute leads the world in the development of bioprintable, biopolymer-based technologies poised to revolutionize drug delivery, wearable and implantable devices. Jointly with HTL we expect to bring to life a new generation of biopolymer-based applications in critical sectors of precision and regenerative medicine," added Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation.

"Microneedle compositions and fabrication technology, and bioprinting for tissue engineering and organoid production have both reached maturity over the last decade. This partnership will accelerate innovation in biopolymers and bring medical solutions to life that can benefit patients" said Glenn Prestwich, HTL's US Science and innovation Advisor.

Discussions between the two parties on the areas of research to be investigated will continue with the stated ambition of meeting unmet medical needs for patients, such as eliminating pain, replacing injections with non-invasive methods or facilitating the administration of treatments. This new step could lead to a final agreement in the coming months.

About HTL

HTL is a biotechnology company at the forefront of the development and production of pharmaceutical grade biopolymers for premium medical products. For over 25 years, its cutting-edge R&D has allowed to develop unique solutions to meet the innovation needs of its clients. HTL serves the healthcare industries worldwide enabling them to transform lives of patients.

www.htlbiotech.com

About the Terasaki Institute for Biomedical Innovation

The TIBI is a non-profit research organization that invents and fosters practical solutions that restore or enhance the health of individuals. The Institute is made possible through an endowment from the late Dr. Paul I. Terasaki, a pioneer in the field of organ transplant technology.

www.terasaki.org

Contacts:

HTL

Nathalie Chevallon

Communication & marketing manager

+33 7 61 45 26 85

nchevallon@htlbiotech.com

Terasaki Institute

Stewart Han

+1 818-836-4393

shan@terasaki.org